1) Orexin receptor antagonism and 2) Topic of the month: Encephalopathy caused by systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Tom Roth and Joe Herring about their paper on orexin receptor antagonism for treatment of insomnia.Dr. Chafic Karam is reading our e-Pearl of the week about central fourth nerve palsies. In the next part of the podcast Dr. Ted Burns interviews Drs. Steven Lewis and Allison Weathers about drugs that can cause encephalopathy. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (35% effort); and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Roth serves on the scientific advisory boards for Merck, Jazz and Transcept; serves as an editorial board member for Sleep and Sleep Medicine; receives research support from Transcept Pharmaceuticals, Impax Pharmaceuticals, Linguflex LLC and APnes, serves on the speakers' bureau of Purdue Pharma L.P. and is a consultant for Abbott Laboratories, Accadia, Acogolix Inc., Acorda, Actelion Pharmaceuticals Ltd, Addrenex Pharmaceuticals, Inc, Alchemers, Alza Corporation, Ancel, Arena, AstraZeneca, Aventis, AVER, Bayer Schering Pharma, BMS, BTG, Cephalon, Inc., Cypress, Dove, Eisai Inc., Elan Corporation, Eli Lilly and Company, Evotec, Forest Laboratories, Inc., GlaxoSmithKline, Hypnion Inc, Impax Pharmaceuticals, Intec, Intra-Cellular Therapies, Jazz, Johnson & Johnson, King Pharmaceuticals, Lundbeck, Inc., McNeil, MediciNova, Merck, Neurim Pharmaceuticals Ltd, Neurocrine, Neurogen, Novartis, Orexo, Organon Pharmaceuticals, Otsuka Pharmaceuticals, Inc., Prestwick, Proctor & Gamble Pharmaceuticals, Pfizer Inc, Purdue Pharma L.P., Resteva, Roche, Sanofi-aventis, Schoering-Plough Corp., Sepracor Inc., Servier Laboratories, Shire plc, Somaxon Pharmaceuticals, Syrex, Takeda Pharmaceutical Company Limited, TransOral, Yanda, VivoMetrics Inc, Wyeth, Yamanuchi Pharmaceutical, and XenoPort.Dr. Herring is Executive Director, Clinical Neuroscience at Merck; receives research support as an employee at Merck and holds stock options with Merck.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Associate Editor for Continuum: Lifelong Learning in Neurology®; receives royalties for the books: Field Guide to the Neurologic Examination and Neurology for the Non-Neurologist and anticipates receiving royalties for the book: Neurologic Disorders due to Systemic Disease.Dr. Weathers receives honoraria as an AAN speaker.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related